Business Wire

OR-GUROBI-OPTIMIZATION

14.11.2022 15:01:59 CET | Business Wire | Press release

Share
Gurobi 10.0 Delivers Blazing-Fast Speed, Innovative Data Science Integration, and an Enterprise Development and Deployment Experience

Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 10.0. This release provides customers with a boost to its already industry-leading speed, the ability to embed machine learning models directly into Gurobi optimization models, and new tools for model development, monitoring, and advanced diagnosis—so users can solve new types of problems, even faster than before.

Performance Improvements and Advanced Solving Techniques

The Gurobi R&D team continues to push the boundaries of performance—resulting in improvements to existing algorithms and the development of several brand-new techniques. As a result, Gurobi Optimizer 10.0 has achieved the following performance improvements since the release of Gurobi Optimizer 9.5:

Type

Algorithm

Overall speed-up

On >100sec models

LP

Concurrent

10%

25%

Primal Simplex

3%

10%

Dual Simplex

3%

10%

MIP

MILP

13%

24%

Convex MIQP

57%

2.4x*

Convex MIQCP

28%

88%*

Non-Convex MIQCP

51%

2.6x

*MIQP and MIQCP hard model test sets are smaller than for other problem classes.

“We’ve achieved a more than 75x speedup on MILP since version 1.1. But more importantly, Gurobi 10.0 can now solve even more models easily, including some models that were, until now, intractable,” explained Dr. Tobias Achterberg, Vice President of Research and Development at Gurobi Optimization.

Gurobi 10.0 also includes the following advances in the underlying algorithmic framework:

  • New network simplex algorithm – Greatly speeds up solving LPs with network structure.
  • New heuristic for QUBO models, which can arise in quantum optimization – Improves Gurobi's ability to quickly find good feasible solutions for quadratic unconstrained Boolean optimization problems.
  • Significant performance gains on MIPs that contain machine learning models – Results in a more than 10x improvement on certain models that contain embedded neural networks with ReLU activation functions.
  • New optimization-based bound tightening (OBBT) algorithm – Greatly speeds up solving nonconvex MIQCP models.
  • Reorganized concurrent LP solver – Improves performance and reduces memory footprint.

Innovative Data Science Integration

With Gurobi Machine Learning—an open-source Python project to embed trained machine learning models directly into Gurobi—data scientists can more easily tap into the power of mathematical optimization.

Specifically, Gurobi Machine Learning allows users to add a trained machine learning model as a constraint to a Gurobi model (e.g., from scikit-learn, TensorFlow/Keras, or PyTorch). Thus, users can estimate a real-world system by training a machine learning model, and then use this machine learning model as a constraint in Gurobi, in order to optimize controls on that system.

“We’re aiming to connect the world of data science with the world of optimization. With Gurobi, you can take your machine learning ‘black box’ that’s generating your predictions and plug it directly into your optimization model—enabling you to connect your forecasting with optimization,” explained Achterberg.

With this release, we're also making it more convenient to integrate gurobipy model building with pandas objects through a new, dedicated open-source package. (Available on GitHub/PyPI in Q4 2022.)

Enterprise Development and Deployment Experience

To make its solver even more accessible and easy to use, the Gurobi team has integrated new tools for model development, monitoring, and advanced diagnosis:

  • Significant enhancements to the matrix-friendly API in gurobipy – All matrix-friendly modeling objects now support multiple dimensions, and dimension handling leans consistently on NumPy, including broadcasting.
  • New logistic general constraint – Makes it easy to incorporate a constraint in MIP that models the logistic function.
  • NuGet package for .NET – Allows .NET users to download Gurobi directly from the NuGet server.
  • Memory limit parameter that allows graceful exit – Users can set a memory limit and still get the best solution and resume the optimization after the limit was hit.
  • New Compute Server dashboards – The Gurobi Compute Server now includes two new dashboards, enabling users to monitor metrics over time and drill down to the actual activity to better understand the cluster usage and application behavior.
  • Expanded platform support – Gurobi 10.0 includes support for Python 3.11 and Linux on ARM 64-bit.

Gurobi introduced its Web License Service (WLS) for Docker and Kubernetes container environments last year, with the release of Gurobi 9.5. With Gurobi 10.0, the team has expanded WLS to support nearly all types of containerized environments. Moreover, customers can now also obtain WLS licenses that allow them to run Gurobi in virtually all deployment scenarios, including containerized environments, virtual machines, and bare-metal machines, across Linux, macOS, and Windows.

“Our customers love our WLS and the flexibility it provides. And now they can dynamically deploy Gurobi software in even more environments,” explained Duke Perrucci, Gurobi’s Chief Operating Officer.

Additionally, starting with Gurobi 10.0, major product releases—and their subsequent minor and technical product releases—will be supported for a term of three years from the initial major product release date. For example, Gurobi version 10.0.0 (released in November 2022) and minor releases between 10.0 and 11.0 will be supported until November 2025.

“This helps create predictability for our customers, so they know exactly how long a version will be supported,” explained Dr. Sonja Mars, Director of Optimization Support at Gurobi Optimization. “We aim to deliver expert technical guidance and support for our customers—and this policy helps eliminate the guesswork. We want our customers to get the help they need, when they need it.”

Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization added, “We have the absolute best minds in optimization here at Gurobi. Across every department, you’ll find people who aren’t just smart—they’re also deeply committed to our customers and to providing the best possible experience. I’m proud to be a part of this team.”

To learn more about Gurobi 10.0, please visit gurobi.com/whats-new-gurobi-10-0/.

About Gurobi Optimization

With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.

As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.

Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005243/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye